Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003: Time trends in a 15-year national survey

Cancer

Volumn 110, Issue 8, 2007, Pages 1803-1814

  Haldorsen, Ingfrid S ^a,b   Krossnes, Bård K ^a   Aarseth, Jan H ^a   Scheie, David ^c   Johannesen, Tom B ^d   Mella, Olav ^a   Espeland, Ansgar ^a,b  

^a HAUKELAND UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d CANCER REGISTRY OF NORWAY   (Norway)

Author keywords

Incidence; Primary central nervous system lymphoma; Survival; Treatment

Indexed keywords

ALKYLATING AGENT; CARBOPLATIN; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; IDARUBICIN; LOMUSTINE; METHOTREXATE; PREDNISONE; PROCARBAZINE; STEROID; TEMOZOLOMIDE; THIOTEPA; TROFOSFAMIDE; VINCRISTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INCIDENCE; CANCER RADIOTHERAPY; CANCER REGISTRY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM TUMOR; CLINICAL FEATURE; CYTOLOGY; DELAYED DIAGNOSIS; DRUG FATALITY; DRUG MEGADOSE; FEMALE; HEALTH SURVEY; HISTOPATHOLOGY; HUMAN; IMMUNE DEFICIENCY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; NORWAY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERFORMANCE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; COMBINED MODALITY THERAPY; FEMALE; HEALTH SURVEYS; HUMANS; INCIDENCE; LYMPHOMA; MALE; MIDDLE AGED; NORWAY; PROGNOSIS; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS;

EID: 35048858045     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22989     Document Type: Article

References (47)

1. Olson JE, Janney CA, Rao RD, et al. The continuing increase in the incidence of primary central nervous system non-Hodgkin lymphoma: a Surveillance, Epidemiology, and End Results analysis. Cancer. 2002;95:1504-1510.
2. Eby NL, Grufferman S, Flannelly CM, Schold SC Jr, Vogel FS, Burger PC. Increasing incidence of primary brain lymphoma in the US. Cancer. 1988;62:2461-2465.
3. Corn BW, Marcus SM, Topham A, Hauck W, Curran WJ Jr. Will primary central nervous system lymphoma be the most frequent brain tumor diagnosed in the year 2000? Cancer. 1997;79:2409-2413.
4. Lutz JM, Coleman MP. Trends in primary cerebral lymphoma. Br J Cancer. 1994;70:716-718.
5. van der Sanden GA, Schouten LJ, van Dijck JA, van Andel JP, van der Maazen RW, Coebergh JW; Working Group of Specialists in Neuro-Oncology in the Southern and Eastern Netherlands. Primary central nervous system lymphomas: incidence and survival in the Southern and Eastern Netherlands. Cancer. 2002;94:1548-1556.
6. Makino K, Nakamura H, Kino T, Takeshima H, Kuratsu J. Rising incidence of primary central nervous system lymphoma in Kumamoto, Japan. Surg Neurol. 2006;66:503-506.
7. Hao D, DiFrancesco LM, Brasher PM, et al. Is primary CNS lymphoma really becoming more common? A population-based study of incidence, clinicopathological features and outcomes in Alberta from 1975 to 1996. Ann Oncol. 1999;10:65-70.
8. Krogh-Jensen M, D'Amore F, Jensen MK, et al. Clinicopathological features, survival and prognostic factors of primary central nervous system lymphomas: trends in incidence of primary central nervous system lymphomas and primary malignant brain tumors in a well-defined geographical area. Population-based data from the Danish Lymphoma Registry, LYFO, and the Danish Cancer Registry. Leuk Lymphoma. 1995;19:223-233.
9. Yau YH, O'Sullivan MG, Signorini D, Ironside JW, Whittle IR. Primary lymphoma of central nervous system in immunocompetent patients in south-east Scotland [letter]. Lancet. 1996;348:890.
10. Au WY, Chan AC, Srivastava G, Leung SY, Liang R. Incidence and pathology of primary brain lymphoma in Hong Kong Chinese patients. Leuk Lymphoma. 2000;37:175-179.
11. Powari M, Radotra B, Das A, Banerjee AK. A study of primary central nervous system lymphoma in northern India. Surg Neurol. 2002;57:113-116.
12. Sarkar C, Sharma MC, Deb P Singh R, Santosh V, Shankar SK. Primary central nervous system lymphoma - a hospital-based study of incidence and clinicopathological features from India, 1980-2003. J Neurooncol. 2005;71:199-204.
13. Haldorsen IS, Aarseth JH, Hollender A, Larsen JL, Espeland A, Mella O. Incidence, clinical features, treatment and outcome of primary central nervous system lymphoma in Norway. Acta Oncol. 2004;43:520-529.
14. Panageas KS, Elkin EB, DeAngelis LM, Ben Porat L, Abrey LE. Trends in survival from primary central nervous system lymphoma, 1975-1999 - A population-based analysis. Cancer. 2005;104:2466-2472.
15. Nelson DF. Radiotherapy in the treatment of primary central nervous system lymphoma (PCNSL). J Neurooncol. 1999;43:241-247.
16. Shibamoto Y, Ogino H, Hasegawa M, et al. Results of radiation monotherapy for primary central nervous system lymphoma in the 1990s. Int J Radiat Oncol Biol Phys. 2005;62:809-813.
17. Ferreri AJ, Reni M, Villa E. Therapeutic management of primary central nervous system lymphoma: lessons from prospective trials. Ann Oncol. 2000;11:927-937.
18. Shah GD, DeAngelis LM. Treatment of primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005;19:611-627.
19. O'Brien PC, Roos DE, Pratt G, et al. Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group). Int J Radiat Oncol Biol Phys. 2006;64:408-413.
20. Abrey LE, DeAngelis LM, Yahalom J. Long-term survival in primary CNS lymphoma. J Clin Oncol. 1998;16:859-863.
21. Herrlinger U, Schabet M, Brugger W, et al. Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects after combined modality treatment. Cancer. 2001;91:130-135.
22. Blay JY, Conroy T, Chevreau C, et al. High-dose methotrexate for the treatment of primary cerebral lymphomas: analysis of survival and late neurologic toxicity in a retrospective series. J Clin Oncol. 1998;16:864-871.
23. Herrlinger U, Schabet M, Bitzer M, Petersen D, Krauseneck P. Primary central nervous system lymphoma: from clinical presentation to diagnosis. J Neurooncol. 1999;43:219-226.
24. Bataille B, Delwail V, Menet E, et al. Primary intracerebral malignant lymphoma: report of 248 cases. J Neurosurg. 2000;92:261-266.
25. Remick SC, Diamond C, Migliozzi JA, et al. Primary central nervous system lymphoma in patients with and without the acquired immune deficiency syndrome. A retrospective analysis and review of the literature. Medicine (Baltimore). 1990;69:345-360.
26. Coulon A, Lafitte F, Hoang-Xuan K, et al. Radiographic findings in 37 cases of primary CNS lymphoma in immunocompetent patients. Eur Radiol. 2002;12:329-340.
27. Erdag N, Bhorade RM, Alberico RA, Yousuf N, Patel MR. Primary lymphoma of the central nervous system: typical and atypical CT and MR imaging appearances. AJR Am J Roentgenol. 2001;176:1319-1326.
28. Haldorsen IS, Espeland A, Larsen JL, Mella O. Diagnostic delay in primary central nervous system lymphoma. Acta Oncol. 2005;44:728-734.
29. Shenkier TN, Voss N, Chhanabhai M, et al. The treatment of primary central nervous system lymphoma in 122 immunocompetent patients: a population-based study of successively treated cohorts from the British Colombia Cancer Agency. Cancer. 2005;103:1008-1017.
30. Jaffe ES, International Agency for Research on Cancer. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
31. Krogh-Jensen M, D'Amore F, Jensen MK, et al. Incidence, clinicopathological features and outcome of primary central nervous system lymphomas. Population-based data from a Danish lymphoma registry.Danish Lymphoma Study Group, LYFO. Ann Oncol. 1994;5:349-354.
32. Goldkuhl C, Ekman T, Wiklund T, Telhaug R. Age-adjusted chemotherapy for primary central-nervous system lymphoma - a pilot study. Acta Oncol. 2002;41:29-35.
33. Johannesen TB, Angell-Andersen E, Tretli S, Langmark F, Lote K. Trends in incidence of brain and central nervous system tumors in Norway, 1970-1999. Neuroepidemiology. 2004;23:101-109.
34. The Cancer Registry of Norway. Cancer in Norway Report, 2003. Oslo, Norway: Cancer Registry of Norway, Institute of Population-Based Cancer Research; 2005.
35. Fitzsimmons A, Upchurch K, Batchelor T. Clinical features and diagnosis of primary central nervous system lymphoma. Hematol Oncol Clin North Am. 2005;19:689-703.
36. Kuker W, Nagele T, Korfel A, et al. Primary central nervous system lymphomas (PCNSL): MRI features at presentation in 100 patients. J Neurooncol. 2005;72:169-177.
37. Harting I, Hartmann M, Jost G, et al. Differentiating primary central nervous system lymphoma from glioma in humans using localised proton magnetic resonance spectroscopy. Neurosci Lett. 2003;342:163-166.
38. Hartmann M, Heiland S, Harting I, et al. Distinguishing of primary cerebral lymphoma from high-grade glioma with perfusion-weighted magnetic resonance imaging. Neurosci Lett. 2003;338:119-122.
39. Ferreri AJM, Reni M. Prognostic factors in primary central nervous system lymphomas. Hematol Oncol Clin North Am. 2005;19:629-649.
40. Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266-272.
41. Hayabuchi N, Shibamoto Y, Onizuka Y. Primary central nervous system lymphoma in Japan: a nationwide survey. Int J Radiat Oncol Biol Phys. 1999;44:265-272.
42. Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711-5715.
43. Omuro AM, Abrey LE. Chemotherapy for primary central nervous system lymphoma [resource online]. Neurosurg Focus. 2006;21:E12.
44. Ferreri AJM, Reni M, Pasini F, et al. A multicenter study of treatment of primary CNS lymphoma. Neurology. 2002;58:1513-1520.
45. Shibamoto Y, Tsuchida E, Seki K, et al. Primary central nervous system lymphoma in Japan 1995-1999: changes from the preceding 10 years. J Cancer Res Clin Oncol. 2004;130:351-356.
46. Corry J, Smith JG, Wirth A, Quong G, Liew KH. Primary central nervous system lymphoma: age and performance status are more important than treatment modality. Int J Radiat Oncol Biol Phys. 1998;41:615-620.
47. Bessell EM, Lopez-Guillermo A, Villa S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by 2 different radiotherapy treatments. J Clin Oncol. 2002;20:231-236.